Risk stratification by the virtual crossmatch: A prospective study in 233 renal transplantations

Transplant International

Volumn 24, Issue 6, 2011, Pages 560-569

  Amico, Patrizia ^a   Hirt Minkowski, Patricia ^a   Hönger, Gideon ^a   Gürke, Lorenz ^a   Mihatsch, Michael J ^b   Steiger, Jürg ^a   Hopfer, Helmut ^b   Schaub, Stefan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

antibody mediated rejection; HLA antibodies; risk stratification; virtual crossmatch

Indexed keywords

CREATININE; GLOBULIN; IMMUNOGLOBULIN;

ADULT; AGED; ANTIBODY RESPONSE; BLOOD GROUP TYPING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOTOXICITY; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; T LYMPHOCYTE; VIRTUAL REALITY;

ADOLESCENT; ADULT; AGED; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; TISSUE DONORS; USER-COMPUTER INTERFACE;

EID: 79955550407     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01235.x     Document Type: Review

References (47)

1. Patel R, Terasaki PI,. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
2. Gebel HM, Bray RA, Nickerson P,. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 2003; 3: 1488.
3. Patel AM, Pancoska C, Mulgaonkar S, Weng FL,. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007; 7: 2371.
4. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI,. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75: 43.
5. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: the emory algorithm. Am J Transplant 2006; 6: 2307.
6. Bingaman AW, Murphey CL, Palma-Vargas J, Wright F,. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation. Transplantation 2008; 86: 1864.
7. Cecka JM,. Calculated PRA (CPRA): the new measure of sensitization for transplant candidates. Am J Transplant 2010; 10: 26.
8. Bielmann D, Honger G, Lutz D, Mihatsch MJ, Steiger J, Schaub S,. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 2007; 7: 626.
9. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S,. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009; 87: 1681.
10. Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC,. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation 2008; 85: 1200.
11. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398.
12. van den Berg-Loonen EM, Billen EV, Voorter CE, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008; 85: 1086.
13. Vlad G, Ho EK, Vasilescu ER, et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol 2009; 70: 589.
14. Morris GP, Phelan DL, Jendrisak MD, Mohanakumar T,. Virtual crossmatch by identification of donor-specific anti-human leukocyte antigen antibodies by solid-phase immunoassay: a 30-month analysis in living donor kidney transplantation. Hum Immunol 2010; 71: 268.
15. Zangwill S, Ellis T, Stendahl G, Zahn A, Berger S, Tweddell J,. Practical application of the virtual crossmatch. Pediatr Transplant 2007; 11: 650.
16. Klitz W, Maiers M, Spellman S, et al. New HLA haplotype frequency reference standards: high-resolution and large sample typing of HLA DR-DQ haplotypes in a sample of European Americans. Tissue Antigens 2003; 62: 296.
17. Bachler K, Amico P, Honger G, et al. Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies. Am J Transplant 2010; 10: 1254.
18. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582.
19. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753.
20. Amico P, Honger G, Bielmann D, et al. Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigen-antibodies. Transplantation 2008; 85: 1557.
21. Zou Y, Stastny P, Susal C, Dohler B, Opelz G,. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357: 1293.
22. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558.
23. Alvarez-Marquez A, Aguilera I, Gentil MA, et al. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies. Transplantation 2009; 87: 94.
24. Goral S, Prak EL, Kearns J, et al. Preformed donor-directed anti-HLA-DP antibodies may be an impediment to successful kidney transplantation. Nephrol Dial Transplant 2008; 23: 390.
25. Vaidya S, Hilson B, Sheldon S, Cano P, Fernandez-Vina M,. DP reactive antibody in a zero mismatch renal transplant pair. Hum Immunol 2007; 68: 947.
26. Haas M, Montgomery RA, Segev DL, et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576.
27. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561.
28. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
29. Akalin E, Dinavahi R, Friedlander R, et al. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 2008; 3: 1160.
30. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
31. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754.
32. Bartel G, Wahrmann M, Regele H, et al. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am J Transplant 2010; 10: 2033.
33. Cai J, Terasaki PI, Anderson N, Lachmann N, Schonemann C,. Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure. Transplantation 2009; 88: 226.
34. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, Lee JH, El-Awar N, Alberu J,. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86: 1111.
35. El-Awar N, Terasaki PI, Nguyen A, et al. Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol 2009; 70: 844.
36. Aubert V, Venetz JP, Pantaleo G, Pascual M,. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 2009; 70: 580.
37. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684.
38. Kushihata F, Watanabe J, Mulder A, Claas F, Scornik JC,. Human leukocyte antigen antibodies and human complement activation: role of IgG subclass, specificity, and cytotoxic potential. Transplantation 2004; 78: 995.
39. Tan CD, Sokos GG, Pidwell DJ, et al. Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection. Am J Transplant 2009; 9: 2075.
40. Salama AD, Delikouras A, Pusey CD, et al. Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant 2001; 1: 260.
41. Amico P, Honger G, Steiger J, Schaub S,. Utility of the virtual crossmatch in solid organ transplantation. Curr Opin Organ Transplant 2009; 14: 656.
42. Zachary AA, Sholander JT, Houp JA, Leffell MS,. Using real data for a virtual crossmatch. Hum Immunol 2009; 70: 574.
43. El-Awar NR, Akaza T, Terasaki PI, Nguyen A,. Human leukocyte antigen class I epitopes: update to 103 total epitopes, including the C locus. Transplantation 2007; 84: 532.
44. Marrari M, Duquesnoy RJ,. Correlations between Terasaki's HLA class II epitopes and HLAmatchmaker-defined eplets on HLA-DR and -DQ antigens. Tissue Antigens 2009; 74: 134.
45. Taylor CJ, Kosmoliaptsis V, Sharples LD, et al. Ten-year experience of selective omission of the pretransplant crossmatch test in deceased donor kidney transplantation. Transplantation 2010; 89: 185.
46. Ren Q, Paramesh A, Yau CL, et al. Long-term outcome of highly sensitized African American patients transplanted with deceased donor kidneys. Transpl Int 2011; 24: 259.
47. Tambur AR, Leventhal JR, Friedewald JJ, Ramon DS,. The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation 2010; 90: 1117.